AU2022300061A1 - Acylated insulin-containing pharmaceutical composition - Google Patents

Acylated insulin-containing pharmaceutical composition Download PDF

Info

Publication number
AU2022300061A1
AU2022300061A1 AU2022300061A AU2022300061A AU2022300061A1 AU 2022300061 A1 AU2022300061 A1 AU 2022300061A1 AU 2022300061 A AU2022300061 A AU 2022300061A AU 2022300061 A AU2022300061 A AU 2022300061A AU 2022300061 A1 AU2022300061 A1 AU 2022300061A1
Authority
AU
Australia
Prior art keywords
yglu
human insulin
desb30 human
ethoxy
eicosanedioyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022300061A
Other languages
English (en)
Inventor
Juanjuan Bi
Wei Chen
Zhongru Gan
Jianghong NIU
Zaiyu WANG
Fangkai XUE
Man ZHANG
Yining Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of AU2022300061A1 publication Critical patent/AU2022300061A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2022300061A 2021-06-25 2022-06-24 Acylated insulin-containing pharmaceutical composition Pending AU2022300061A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110709826.5 2021-06-25
CN202110709826 2021-06-25
PCT/CN2022/101204 WO2022268208A1 (zh) 2021-06-25 2022-06-24 含酰化胰岛素的药物组合物

Publications (1)

Publication Number Publication Date
AU2022300061A1 true AU2022300061A1 (en) 2024-02-01

Family

ID=84544235

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022300061A Pending AU2022300061A1 (en) 2021-06-25 2022-06-24 Acylated insulin-containing pharmaceutical composition

Country Status (7)

Country Link
US (1) US20250262282A1 (https=)
EP (1) EP4361174A4 (https=)
JP (1) JP2024522904A (https=)
CN (1) CN118139875A (https=)
AU (1) AU2022300061A1 (https=)
CA (1) CA3228912A1 (https=)
WO (1) WO2022268208A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117561072A (zh) * 2021-06-25 2024-02-13 甘李药业股份有限公司 含glp-1化合物的药物组合物
CN116327890B (zh) * 2023-05-29 2023-12-08 北京先为达生物科技有限公司 口服递送的组合物及其应用
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
WO2025098502A1 (zh) * 2023-11-08 2025-05-15 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371361T3 (es) * 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
BRPI0820535B8 (pt) * 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
WO2012080320A1 (en) * 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
KR20140104994A (ko) 2011-12-15 2014-08-29 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체 및 이의 아실화 유도체
CN104364260B (zh) * 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
CN104689302B (zh) * 2015-02-05 2017-06-23 通化东宝药业股份有限公司 一种地特胰岛素注射液的制备方法及其制备的地特胰岛素注射液
WO2018024186A1 (zh) 2016-08-02 2018-02-08 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
PE20210857A1 (es) * 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
CN110386974B (zh) * 2018-04-19 2022-12-09 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物

Also Published As

Publication number Publication date
JP2024522904A (ja) 2024-06-21
EP4361174A1 (en) 2024-05-01
WO2022268208A1 (zh) 2022-12-29
CN118139875A (zh) 2024-06-04
CA3228912A1 (en) 2022-12-29
EP4361174A4 (en) 2025-11-19
US20250262282A1 (en) 2025-08-21

Similar Documents

Publication Publication Date Title
US20250228919A1 (en) Insulin Derivative
AU2022300061A1 (en) Acylated insulin-containing pharmaceutical composition
JP2023510206A5 (https=)
JP2023510219A5 (https=)
US20250340610A1 (en) Acylated insulin
HK40103864A (en) Acylated insulin-containing pharmaceutical composition
EA050726B1 (ru) Производное инсулина
HK40070502A (zh) 胰岛素衍生物
EA050813B1 (ru) Производное инсулина
HK40070502B (zh) 胰岛素衍生物